Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Unknown
Route of Administration: Intravenous, Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Amgen
Company Location: Western America
Company Founding Year: 1980
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07590193 |
NCT07590193 | P1 |
Not yet recruiting |
Type 2 Diabetes |
2027-10-02 |
50% |
2026-05-16 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|